P-178 Quality of Life Improvement Correlates with Clinical Remission in Patients with Active Crohn's Disease in Filgotinib Phase 2 FITZROY Study

    loading  Checking for direct PDF access through Ovid



Filgotinib is a once daily, oral, selective Janus kinase 1 (JAK1) inhibitor, which has demonstrated efficacy in patients with rheumatoid arthritis. Here we analyse patient reported outcomes in patients with moderate-to-severely active Crohn's disease (CD) from the Fitzroy Ph2 study.


One hundred seventy-four patients with moderate-to-severely active CD (CDAI: 220–450, evidence of active disease by centrally-read endoscopy) were randomized (3:1 ratio) to receive 200 mg filgotinib (FIL) or placebo (PBO) QD for 10 weeks. Immunosuppressants were discontinued prior to treatment initiation. Based on clinical response at Week 10, patients continued to receive filgotinib (200 or 100 mg QD) or placebo for an additional 10 weeks. Both TNF-antagonist naïves and non-responders were included. Clinical efficacy, safety, and patient reported outcomes (IBDQ and PRO2) data from the first 10-week part are presented.


Baseline characteristics were similar in both groups, including mean disease duration (8.3 yr), mean CDAI score (293), mean SES-CD (14.6), oral corticosteroids (51%, mean daily dose 20.8 mg/d). The primary endpoint of the study was met: FIL induced clinical remission (CDAI < 150) in 47% of the patients, compared to 23% of those assigned to PBO (P = 0.0077). At week 10, quality of life, assessed by patient reported outcome PRO2 (PRO2: 7 × [mean daily number of liquid or very soft stools] + 7 × [mean daily abdominal pain score] [mean change from baseline FIL: −21.9; PBO: −15.6; P = 0.0321]) as well as IBDQ score (mean change from baseline FIL: 33.8; PBO: 17.6; P = 0.0046) improved significantly more in FIL compared to PBO. Effect of FIL on IBDQ was evident in all IBDQ subcomponents (mean change from baseline): bowel symptoms (FIL: 10.0; PBO: 5.6; P = 0.0040), systemic symptoms (FIL: 5.7; PBO: 2.9; P = 0.0044), emotional status (FIL: 12.1; PBO: 6.1; P = 0.0094), and social functioning (FIL: 6.2; PBO: 2.9; P = 0.0202). The IBDQ remission (IBDQ score ≥ 170) (FIL: 45%; PBO: 27%; P = 0.0505) and IBDQ response (change in IBDQ score ≥16) (FIL: 64%; PBO: 41%; P = 0.0137) were higher with FIL compared to PBO. The patient's general well-being (CDAI component, mean change from baseline FIL: −0.98; PBO: −0.65; P = 0.1024) improved more with FIL compared to PBO at week 10, but statistical significance was not reached. Improvements in clinical CDAI responses correlated with improvements in patient reported outcomes. Overall, filgotinib was safe and well tolerated. The rates of early discontinuation, SAEs and TEAEs including infections were similar in the FIL and PBO groups; the majority of the SAEs was related to worsening of CD.


Filgotinib is the first JAK inhibitor to show efficacy in moderate-to-severely active CD. JAK1 inhibition with filgotinib induces clinical remission, associated with improved quality of life as demonstrated by patient-reported outcome measures. The efficacy and safety profile of filgotinib demonstrates its potential as an oral treatment with a novel mechanism of action for the treatment of CD.

Related Topics

    loading  Loading Related Articles